INTRODUCTION
Calcitonins (CT)1 from several species have been administered for prolonged periods by several groups of investigators in attempts to suppress the rapid skeletal turnover exhibited by subjects with Paget's disease of bone (1) (2) (3) (4) (5) . Porcine, human, and salmon calcitonins have been used with subsequent observation of reduced urinary hydroxyproline excretion and decreased serum alkaline phosphatase. The precise amino acid sequences of these calcitonins are known to differ (6) (7) (8) , and salmon calcitonin is recognized to be a more potent hypocalcemic agent in mammalian bioassay systems (9). We have observed rebound increases of serum alkaline phosphatase in resistance to salmon and porcine calcitonin in subjects with Paget's disease of bone.
METHODS
Patients. 15 patients with Paget's disease of bone received varying amounts of partially purified (30% pure) porcine calcitonin2 and/or extracted salmon calcitonin, 3 and/or synthetic salmon calcitonin4 in varying dosage schedules over periods ranging from 4 to 24 months. Baseline evaluation, skin testing, and initial administration of the hormones were carried out in a clinical research center. Serum calcium and alkaline phosphatase activity (KingArmstrong units, normal adult range 7-17 KAU) were determined on a Technicon AutoAnalyzer. Original metabolic observations with porcine calcitonin in three of the subjects have been previously reported (2) . Since cubations at 4°C, coated charcoal was used to adsorb "free" hormone. The reciprocal of the total amount of hormone (1/T; abscissa) was plotted against the reciprocal of the amount of hormone bound (1/B). A linear slope was drawn by the method of least squares, and the ordinate intercept was taken as the reciprocal of the maximal binding capacity for the amount of serum tested (13).
Serum neutralization of calcitonin in rat bioassay.9 Sera were heated at 56'C for 20 min to inactivate enzymes, and then diluted with saline in siliconized glass tubes. Calcitonin (20 mU/tube) was dissolved in 1%o gelatin-saline and mixed with the diluted serum at a concentration of 20 mMRCU/ml. Tubes were incubated at room temperature for exactly 30 min, and the contents injected into 100-130 g female Sprague-Dawley rats that had been fasted for 16 hr. Six rats were used for each group, each rat receiving 10 mU/100 g (0.5 ml) subcutaneously. 30 min after injection each group of rats was anesthetized with ether and bled from the abdominal aorta. Serum calcium was determined on a Technicon AutoAnalyzer (14) . As controls, calcitonin was added to normal sera treated as described above, and injected into separate groups of rats at 5, 10, and 15 mU/100 g subcutaneously.
Administration of intravenous SCT-"'I. SCT-1`I was eluted from micro-fine silica'0 with 33% acetone in 1% acetic acid. After evaporation of the acetone under a stream of nitrogen, the eluate was passed through a Millipore filter into a vial of sterile isotonic saline. Before and after injection, syringes, needles, and their contents were counted in an Armac spectrometer "' in order to calculate precise dosages. In resistant subjects, no calcitonin had been administered for at least 5 days before the study. All subjects were given 25 ,ug of triiodothyronine four times daily for 4 days before and 3 days after the study. An indwelling needle was placed in the vein of one arm and kept patent with a slow infusion of 5% dextrose solution. Preinjection sera were obtained and the SCT-"I was rapidly (5 sec) injected into a vein in the contralateral arm. Serial blood and urine samples were obtained thereafter, with no interruption of meal schedules. Blood was allowed to clot for 30 min at room temperature, and serum was obtained by centrifugation at 50C. Portions of serum were assayed for total radioactivity and that radioactivity precipitated by exposure of serum to equal volumes of saturated (NH4)2SO4. Urine samples were collected into plastic bottles, and their radioactivity was measured in the Armac counter. The data were collated by taking into account the relative efficiencies of "I measurement by the Armac (6%o) and well-type counter (33%,) and expressed as percentage of the dose administered.
RESULTS Clinical observationts. The limited availability and early interdiction of out-patient administration of calcitonin preparations, as well as patients' choices, resulted in an irregular sequence of administration and dosage of the porcine and salmon hormones. 15 patients received calcitonin injections daily or thrice weekly for 4 months or longer and are reported in this study. ' We are grateful to Dr. J. P. Aldred of Armour Pharmaceuticals for kindly performing the rat bioassay neutralization studies.
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Occasional "flush" sensations and xerostomia were reported by several of the patients after intravenous injections of calcitonin, but no abnormalities of the urine sediment, hemogram, or chemical profile were observed in any of the subjects. Changes in the radiographic appearance of the skeleton were not observed during the period of hormone administration. Fig. 1 depicts the serum alkaline phosphatase responses of 14/15 patients during calcitonin administration. One subject not included in the figure had a normal alkaline phosphatase level before SCT administration, and her serum did not acquire the ability to bind SCT-'I after 6 months of hormone injections. All 14 subjects shown experienced a reduction in serum alkaline phosphatase activity (mean decrease of 49%) within 4 months after initiating therapy. Within the next 4 months, however, a rise in enzyme activity was observed in four patients. Two additional patients exhibited increased phosphatase activity as high as or above pretreatment levels by the end of 1 yr. Of the eight other patients shown, six have been followed for 8 months or longer. Five have shown either continued mild suppression or a plateau in phosphatase activity, and one subject has experienced a sustained decrease to < 20% of pretreatment levels (158-25 KAU). Nine of the 14 subjects reported some relief of bone pain during therapy, and four of these later exhibited a rebound in phosphatase activity in spite of continued hormone administration. Two patients experiencing rebound elevations of phosphatase and two patients exhibiting con- 12 patients. A decrease in serum calcium of at least 0.8 mg/100 ml was observed in each instance. Fig. 2 shows the acute serum calcium response to calcitonin before and during therapy by 4/6 subjects who exhibited a rise in alkaline phosphatase in spite of continued hormone administration. L. A. H. and H. E. L. showed with the sera from the treated subjects who experienced sustained lowering of alkaline phosphatase activity (8/8) and sustained hypocalcemic responsiveness (7/7). In contrast, the sera from the six patients who experienced rebound elevations of serum phosphatase acquired the ability to bind labeled calcitonin (Table I and Fig. 1 ).
Chromatoelectrophoresis of incubations of patients' sera witlh SCT-'=I is depicted in Fig. 3 . Migration of radioactivity to strip segments of the gamma globulin region was observed in H. E. L., L. A. H., and M. I. S., whereas S(CT-"I and control serum incubations resulted in little anodal migration of radioactivity. The reversible association of SCT-'I is indicated by the lack of anodal migration of radioactivity when L. A. H.'s serum incubation contained 100 m/g of unlabeled SCT. Similar results (not shown) were obtained with sera from T. H. C., H. A. C., and B. I. P.
Incubations of M. I. S. serum with SCT-'I resulted in the sedimentation of radioactivity in a region of the sucrose density ultracentrifugation pattern like that of human 7S gamma globulin (Fig. 4) . Addition of 100 mug of unlabeled SCT resulted in the failure of sedimentation of the SCT-'5I, similar to the results observed with analyses of control serum.
Competitive displacement of SCT-`I and PCT-'"I from the serum of M. I. S. was studied (Fig. 5) PCT. However, both SCT and HCT were weakly competitive to this binding. Sera from T. H. C. also bound SCT-`2I and PCT-'I well, but SCT was equally capable of displacing both tracers. In contrast, sera from H. E. L., B. I. P., and L. A. H. only weakly bound PCT-121I, and this binding was easily reversed by addition of PCT or SCT in amounts < 10 mAg, but not by 1 Ag of HCT. Rabbit anti-human gamma globulin serum precipitated radioactivity from incubations of M. I. S. and T. H. C. sera with PCT-'I and SCT-10I, as well as incubations of H. E. L., B. I. P., H. A. C., and L. A H sera with SCT-NI. Fig. 6 shows the results of a study in which in vitro incubations of M. I. S. sera with calcitonins-"I were subjected to agar electrophoresis and allowed to diffuse against rabbit anti-human serum (Fig. 6, upper) . After extensive washing of the gel slides, large amounts of radioactivity in the gamma globulin precipitation lines vere detectable in the autoradiograph (Fig. 6, lower) . The maximal binding and neutralizing capacities of the sera from the patients with apparent resistance to calcitonin are shown in Table I . Although sera for in vitro studies were always obtained > 20 hr after prior injections of calcitonin, the possibility of occupied binding sites in such sera suggests our estimates of maximal binding to actually be low. After cessation of therapy, the binding capacity and neutralizing ability of M. I. S. and L. A. H. sera have been observed to decrease. As shown in Table I , the rat bioassay neutralization data correlate reasonably well with the estimates of serum binding capacity and phosphatase levels.
Disappearance of SCT-I251 from serum. The disappearance of total radioactivity from the serum after intravenous administration of SCT-15I was delayed in those subjects displaying resistance to the hormone (Fig. 7) . In addition, the percentage of serum radioactivity precipitable with 50% (NH4)2SO4 was higher in these patients. The salt-precipitable radioactivity was considerable in the nonresistant subjects as well during the early postinjection period. In vitro incubation of preinjection serum with SCT-'25I for 37°C for 2 hralso showed more radioactivity to be salt-precipitable in the resistant groups. It is possible that some of this precipitated radioactivity reflects trapped peptide in addition to association with antibody molecules. The continued high percentage of precipitable radioactivity w-e observed in the resistant sera is similar to that reported by Berson et al. tusing sodium sulfate treatment of serat takenl from insulin-treated diabetics after intravenous administration of insulin-"1'I (12). In addition, significantly less radioactivity was recovered in the urine of the resistant subjects compared with those subjects who were sensitive or not previously exposed to calcitonin (data not shown).
DISCUSSION
The retardation of disappearance of SCT-'"I from the blood stream (3/3), its altered migration on paper electrophoresis and its precipitation by anti-human gamma globulin serum after incubation with these patients' sera (6/6) compared with control collectively p)rovide strong evidence for the presence of antibodies to calcitonin in the subjects studied. In addition, these sera were capable of neutralizing the hypocalcemic potency of calcitonin in the rat bioassay. figure. Lower figure: The slide was then placed in a tank containing 500 ml of phosphate buffered 0.15 M saline and-allowed to rinse with continued gentle stirring of wash solution for 72 hr. The buffer was ged each day with final rinse consisting of distilled water.
After air-drying, the slide was placed under film and an autoradiograph was developed. The well with the level of serum phosphatase or serum binding and neutralization of calcitonin, but the protocol was not double blind, therefore limiting the validity of the reports of pain relief. The prompt response of hypocalcemia to the other calcitonin species (Fig. 2) indicates high skeletal turnover and shows that the failure to respond to the original calcitonin cannot be explained by secondary changes in mineral homeostasis. Several investigators have reported their observations employing calcitonin in Paget's disease of bone, as well as other skeletal disorders (1) (2) (3) (4) (5) . The failure to observe suppression of skeletal turnover to normal levels in Paget's disease during calcitonin therapy has been thought to indicate secondary hyperparathyroidism (16, 17), even though antibody formation to PCT and SCT has been reported (17, 18) . Others have not detected antibodies but have observed elevations of serum alkaline phosphatase during continued PCT therapy (5) . Although secondary hyperparathyroidism should play a role in homeostatic adjustment to repetitive hypocalcemic stimuli, it could not explain the resistance in our subjects, most of whom responded very well to a different calcitonin. It is possible, however, that resistance to calcitonin in some patients may reflect secondary hyperparathyroidism as well.
Of interest in the finding that human and salmon calcitonins share 14 identical amino acid positions and that the human sequence more closely resembles the salmon than that of the bovine and porcine hormones (8). Several subjects exposed to both hormones demonstrated binding in vitro of both PCT-mI and SCT-'I.
Of those sera thus far tested, only M. I. S. demonstrates specific binding of both hormones, most likely demonstrating the presence of two distinct antibody populations in her serum. It is also not clear whether the slight cross-reactivity of her PCT antibody with SCT might indicate that her course of SCT therapy provided a stimulation of the antibodies to PCT. 
